View More Recent Stories
-
Editas Medicine (EDIT) Announces Progress Towards 2024 Goals, Including Achievement of In Vivo Preclinical Proof of Concept and Strategic Update
-
Leerink Partners Reiterates Market Perform Rating on Editas Medicine (EDIT)
-
Jones Trading Starts Editas Medicine (EDIT) at Buy
-
Editas Medicine (EDIT) PT Lowered to $12 at Truist Securities
-
Editas Medicine (EDIT) Misses Q2 EPS by 12c
